Isoproterenol-induced Cardiac Dysfunction in Male and Female C57Bl/6 Mice

Short Title: Sex Differences in Cardiac Dysfunction

Marianne K. O. Grant\textsuperscript{a}, Ibrahim Y. Abdelgawad\textsuperscript{a}, Christine A. Lewis\textsuperscript{a}, Davis Seelig\textsuperscript{b}, and Beshay N. Zordoky\textsuperscript{a}\textsuperscript{*}

\textsuperscript{a} Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, United States of America.

\textsuperscript{b} Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, Minnesota, United States of America.

* Corresponding author.

E-mail: zordo001@umn.edu

Phone number: 1-612-625-6499

Postal address: University of Minnesota College of Pharmacy Department of Experimental and Clinical Pharmacology 7-115 Weaver-Densford Hall 308 Harvard St. SE Minneapolis, MN 55455

Running title: Sex Differences in Cardiac Dysfunction
ABSTRACT

Sex-related differences in cardiovascular diseases are complex and context-dependent. The objective of this work was to comprehensively determine key sex differences in the response to acute and chronic adrenergic stimulation in C57Bl/6 mice. Cardiac function was assessed by trans-thoracic echocardiography before and after acute adrenergic stimulation (a single subcutaneous dose of isoproterenol 10 mg/kg) in male and female C57Bl/6 mice. Thereafter, chronic adrenergic stimulation was achieved by sub-cutaneous injections of isoproterenol 10 mg/kg/day for 14 days in male and female mice. Cardiac function and morphometry were assessed by trans-thoracic echocardiography on the 15th day. Thereafter, the mice were euthanized and the hearts were collected. Histopathological analysis of myocardial tissue was performed after staining with hematoxylin & eosin, trichrome, and MAC-2 antibody. Gene expression of remodeling and fibrotic markers was assessed by real-time PCR. Cardiac function and morphometry were also measured before and after isoproterenol 10 mg/kg/day for 14 days in groups of gonadectomized male and female mice and sham-operated controls. In the current work, there were no statistically significant differences in key echocardiographic parameters between male and female C57Bl/6 mice in response to acute adrenergic stimulation. After chronic adrenergic stimulation, there was similar degree of cardiac dysfunction, cardiac hypertrophy, and myocardial fibrosis in male and female mice. Similarly, chronic isoproterenol administration induced hypertrophic and fibrotic genes in hearts of male and female mice to the same extent. Intriguingly, gonadectomy of male and female mice did not have a significant impact on isoproterenol-induced cardiac dysfunction as compared to sham-operated animals. The current work demonstrated lack of significant sex-related differences in isoproterenol-induced cardiac hypertrophy, dysfunction, and fibrosis in C57Bl/6 mice. This study suggests that female sex may not be sufficient to protect the heart against a severe pathologic stimulus and underscores the notion that sexual dimorphism in cardiovascular diseases is highly model-dependent.
Key words: Sex Differences; Isoproterenol; Cardiac Dysfunction; Cardiac Hypertrophy
INTRODUCTION

Cardiovascular diseases remain the leading cause of mortality in both men and women globally [1], despite the conventional dogma that women are more protected against cardiovascular diseases than men. Indeed, the incidence of cardiovascular diseases in post-menopausal women is equal to those in age-matched men [2]. Furthermore, there are a number of cardiovascular diseases that are more prevalent in young pre-menopausal women than in men, including Takotsubo cardiomyopathy [3] and microvascular angina [4]. In addition, there are marked sex differences in the pathogenesis and/or clinical presentation of several cardiovascular diseases. For instance, heart failure with reduced ejection fraction (HFrEF) is more prevalent in men, while heart failure with preserved ejection fraction (HFpEF) is more prevalent in women [5].

The conventional view is that sex-related differences in cardiovascular diseases are mainly attributed to male and female sex hormones [2]. Traditionally, estrogen has been thought to provide a protective effect, whereas testosterone has a detrimental cardiovascular effect. Although supported by a large body of evidence [2], this traditional view could not explain several clinical and preclinical observations including: the worse outcome of post-menopausal women receiving supplemental estrogen therapy [6], post-ischemic cardioprotection in aromatase knock-out mice [7], and worsening of heart failure in castrated male experimental animals [8, 9], suggesting that sexual dimorphism in cardiovascular diseases is complex and context-dependent.

Isoproterenol is a pharmacological agent commonly used to induce a spectrum of cardiac pathologies. A number of studies determined the sex-related differences in the phenotypic manifestations and molecular determinants in models of isoproterenol-induced cardiac hypertrophy with discrepant results. While some of these studies reported that female experimental animals were protected against cardiac hypertrophy and fibrosis in response to chronic administration of low isoproterenol doses (0.04 mg/kg/day for 6 months) [10, 11], other
studies reported no difference in cardiac hypertrophy in response to a higher dose (30 mg/kg/day for 7 days) [12], and one study showed that female rats were more sensitive than males to cardiac fibrosis induced by moderate doses of isoproterenol (7.5 mg/kg/day for 3 weeks) [13]. These studies suggest that sex-related differences in the response to isoproterenol are context-dependent. Since most of the previous work has focused on determining sex-related differences in isoproterenol-induced cardiac hypertrophy and fibrosis [10-13], in the current work, we comprehensively determined key echocardiographic, molecular, and histopathologic sex differences in a model of cardiac dysfunction produced by moderate doses of isoproterenol (10 mg/kg/day for 14 days) in male and female C57Bl/6 mice.

METHODS

Animals

Animal procedures were approved by the Institutional Animal Care and Use Committee at the University of Minnesota. Intact male (n=19) and female (n=19) C57Bl/6 mice were purchased from Charles River Laboratories. Starting at 15 weeks of age, 10 mg/kg isoproterenol (n=12 male, n=12 female) or an equivalent volume of sterile saline (n=7 male, n=7 female) was administered by subcutaneous daily injection for 14 days. Age-matched mice that had been castrated (n=4), ovariectomized (n=4), or sham-operated (n=4 male, n=4 female) by Charles River Laboratories were subjected to the isoproterenol regimen described above. Animals were humanely euthanized by decapitation under isoflurane anesthesia 1 day after the last injection of isoproterenol. Hearts were collected, rinsed in ice-cold phosphate-buffered saline, snap frozen in liquid nitrogen, and stored at -80°C.

Echocardiography

Cardiac function was assessed by echocardiography prior to isoproterenol administration and immediately following the first dose to determine the response to acute isoproterenol
To determine the response to chronic isoproterenol administration, cardiac function was assessed by echocardiography following the last dose of isoproterenol or sterile saline injections (n=7-12 per sex per group). Echocardiography was performed using the Vevo 2100 system (VisualSonics, Inc., Toronto, Ontario, Canada) equipped with an MS400 transducer. Anesthesia was induced with 3% isoflurane in oxygen and maintained at 1-2% during the procedure. Mice were secured in a supine position on a heated physiologic monitoring stage. Parasternal short axis images of the left ventricle were obtained in M-Mode at the level of the papillary muscles. Endocardial and epicardial borders were manually traced over 3-4 cardiac cycles and cardiac output, ejection fraction, fractional shortening, end diastolic and systolic volumes, and left ventricular (LV) Mass were calculated using VisualSonics cardiac measurement package of the Vevo 2100.

**Histopathology**

LV heart sections were collected, fixed in 10% neutral buffered formalin and embedded in paraffin. Four-micron sections were stained with hematoxylin and eosin (HE) or trichrome stain. Histopathologic evaluation was performed by a board certified veterinary pathologist who was blinded to the experimental group. Each stained HE stained section was examined for (a) inflammation (distribution, severity, and cell type), (b) vascular pathology, (c) interstitial fibrosis, and (d) myofiber degeneration / vacuolization. Inflammation and fibrosis were assessed as follows: 0, absent; 1, minimal inflammation or fibrosis; 2, mild minimal inflammation or fibrosis; 3, moderate minimal inflammation or fibrosis; and 4, marked minimal inflammation or fibrosis. For vascular and myofiber pathology, sections were scored based upon the severity of the change (minimal, mild, moderate, or severe) and the morphologic nature of the pathology. The severity of fibrosis on the trichrome stained section was assessed for fibrosis as described above. Sections from each heart were also immunohistochemically stained for expression of MAC-2 (galectin-3). In brief, four-micron sections were dewaxed and rehydrated prior to antigen retrieval.
Thereafter, sections were incubated with either anti-galectin-3 antibody (clone M3/38, Cedarlane Labs, Burlington, NC) according to manufacturer’s instruction. The number of MAC-2 positive cells was manually quantified on the five most cellular 200X images.

**RNA extraction**

Total RNA was extracted from 20 mg frozen heart tissue using 300 µL Trizol reagent (Life Technologies, Carlsbad, CA) according to manufacturer’s instructions. RNA concentrations were attained by measuring absorbance at 260 nm using a NanoDrop 8000 spectrophotometer (Thermo Fisher Scientific, Wilmington, DE) and first-strand cDNA was synthesized from 1.5 µg total RNA using the high-capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA) according to manufacturer’s instructions.

**Real-time PCR**

Specific mRNA expression was quantified by SYBR Green (Applied Biosystems) based real-time PCR performed on an ABI 7900HT instrument (Applied Biosystems) using 384-well optical reaction plates. Thermocycler conditions were as follows: 95°C for 10 min, followed by 40 PCR cycles of denaturation at 95°C for 15 sec, and annealing/extension at 60°C for 1 min. Gene expression was determined using previously published primers for ANP, BNP, and TGF-beta1. Primer sequences are listed in supplementary table 1. The mRNA expression levels were normalized to β-actin and are expressed relative to male control. Relative gene expression was determined by the ΔΔCT method. Primer specificity and purity of the final PCR product were verified by melting curve analysis.

**Statistical analysis**

Data were analyzed using GraphPad Prism software (version 7.01, La Jolla, CA) and are presented as means ± standard errors of the mean (SEM). Comparisons among different sex or
surgical alterations and treatment groups were performed by ordinary two-way analysis of
variance (ANOVA), followed by Tukey’s multiple comparison post-hoc analysis or two-way
ANOVA (repeated measures), followed by Sidak’s post-hoc analysis where appropriate.
Statistical analysis for histopathologic grading and MAC-2 staining was performed using the non-
parametric Kruskal-Wallis test. A $p$ value of $< 0.05$ was taken to indicate statistical significance.

RESULTS

Acute effects of isoproterenol administration on echocardiographic parameters in intact
male and female mice. Cardiac function was assessed by echocardiography prior to and
immediately following a single SC injection of 10 mg/kg isoproterenol in adult male and female
mice. Representative echocardiographic images obtained in M-Mode from each group are
displayed in Fig. 1A. Acute administration of isoproterenol had a similar effect on cardiac function
in males and females. Ejection fraction and fractional shortening were significantly increased to a
similar degree in both sexes. Ejection fraction was increased by 53% in males and 59% in females
(Fig. 1B) and a 110% increase in fractional shortening was evident in both sexes (Fig. 1C). End-
systolic volume was decreased by 90% in both sexes (Fig. 1D) and end-diastolic volumes were
down 35% in male and 30% in female mice (Fig. 1E). Cardiac output was significantly increased
(35%) in female, but not male, mice (Fig. 1F). As expected, acute treatment with isoproterenol
induced a significant increase in heart rate by 22% in male and 13% in female mice (Fig. 1G).
Matched two-way ANOVA revealed a significant effect of isoproterenol on all the measured
parameters, while sex effect was significant only on the cardiac output. There was no significant
interaction between isoproterenol and sex in all the measured parameters (Supplementary Table
2).

Chronic administration of isoproterenol caused significant cardiac dysfunction and
hypertrophy in intact male and female mice. Cardiac function in male and female mice was
assessed by echocardiography following 14 days of treatment with isoproterenol or saline
Representative echocardiographic images obtained in M-Mode from each group are displayed in Fig. 2A. Chronic administration of isoproterenol had a similar effect on cardiac function in male and female mice. Ejection fraction, an accurate measure of systolic dysfunction [14], and fractional shortening were significantly decreased to a similar degree in both sexes when compared to saline treatment of the same sex. Ejection fraction was decreased by 25% in male and 21% in female mice (Fig. 2B). Fractional shortening was decreased by 30% in males and 24% in females (Fig. 2C). End-systolic and diastolic volumes were significantly increased in male (87% and 20%, respectively), but not female mice (Fig. 2D and 2E). Although not significant, a 61% increase in end-systolic volume was evident in female mice, (Fig. 2D) with little change in end-diastolic volume (Fig. 2E). Cardiac output was decreased by 22% in male mice and 19% in female mice, though this decrease did not reach significance in female mice (Fig. 2F). Female mice had significantly smaller hearts than male mice from the same treatment group (Fig. 2G-H). Isoproterenol-treated mice exhibited a significantly greater heart weight/tibia length ratio (HW/TL) compared to saline-treated mice (Fig. 2G). Two-way ANOVA revealed a significant isoproterenol effect on all the measured parameters, while sex effect was significant only in LV Mass and the heart weight/tibia length ratio (HW/TL). There was no significant interaction between isoproterenol and sex in any of the measured parameters (Supplementary Table 3).

**Chronic administration of isoproterenol caused significant pathological lesions in the hearts of intact male and female mice.** Analysis of the HE- and trichrome stained heart sections revealed increased fibrosis in both isoproterenol-treated male and female mice (Fig. 3 and Fig. 4A). The severity of fibrosis did not significantly differ between the male and female mice. Similarly, both male and female treated mice demonstrated significantly higher numbers of MAC-2 positive cells than their control counterparts, but were not significantly different from each other (Fig. 3 and Fig. 4B).

**Chronic administration of isoproterenol induced the gene expression of markers of cardiac remodeling and fibrosis in intact male and female mice.** The mRNA expression levels of the
natriuretic peptides ANP and BNP were increased, though not significantly, in hearts of mice treated with isoproterenol for 14 days (Fig. 5A and 5B). Similar changes were observed in male and female mice in both ANP (2.5- and 3-fold, respectively) (Fig. 5A) and BNP (3- and 3.8-fold, respectively) (Fig. 5B). Gene expression of the fibrotic marker TGF-beta1 was significantly induced following isoproterenol treatment. A significant 2-fold increase in the gene expression of TGF-beta1 was observed in both male and female mice (Fig. 5C). Chronic isoproterenol administration for 14 days had a significant effect on all the measured genes, while neither sex effect nor the interaction between sex and isoproterenol were statistically significant (Supplementary Table 4).

**Effect of castration of male mice on isoproterenol-induced cardiac dysfunction.** Isoproterenol treatment for 14 days resulted in similar functional changes in sham and castrated mice. Representative echocardiographic images obtained in M-Mode from each group are displayed in Fig. 6A. Ejection fraction (Fig. 6B) and fractional shortening (Fig. 6C) were significantly reduced by approximately 20% in both sham and castrated mice. Significant increases in end-systolic volumes (Fig. 6D) were clearly evident in sham and castrated mice (35 and 56%, respectively). End-diastolic volumes (Fig. 6E) were also increased in sham and castrated mice (9 and 15%, respectively), though the increase in sham mice was not statistically significant. Similar decreases in cardiac output (Fig. 6F) were observed in castrated and sham mice, though this decrease was not significant in sham. Isoproterenol administration caused a significant increase in LV mass in both sham and castrated mice (Fig. 6G). Matched two-way ANOVA revealed a significant isoproterenol effect on all the measured parameters. However, the castration effect and the interaction between isoproterenol and castration were not statistically significant (Supplementary Table 5).

**Effect of ovariectomy of female mice on isoproterenol-induced cardiac dysfunction.** Isoproterenol treatment for 14 days resulted in similar functional changes in sham and ovariectomized mice when compared to measures obtained prior to treatment. Representative
echocardiographic images obtained in M-Mode from each group are displayed in Fig. 7A. Ejection fraction and fractional shortening were significantly decreased following isoproterenol treatment in sham (23% and 28%, respectively) and ovariectomized (35% and 42% respectively) mice (Fig. 7B and 7C). ISO treatment resulted in significantly greater end-systolic and diastolic volumes in both sham (99% and 46%, respectively) and ovariectomized (128% and 31%, respectively) mice (Fig. 7D and 7E). Cardiac output was unaltered by isoproterenol treatment in either group (Fig. 7F). Isoproterenol administration caused a significant increase in LV mass in both sham and ovariectomized mice (Fig. 7G). Matched two-way ANOVA revealed a significant isoproterenol effect on all the measured parameters except the cardiac output. However, the ovariectomy effect and the interaction between isoproterenol and ovariectomy were not statistically significant (Supplementary Table 6).

**DISCUSSION**

Sex-related differences have been described in a number of animal models of cardiac hypertrophy/dysfunction. In models of doxorubicin-induced cardiotoxicity, we and others have demonstrated a profound sexual dimorphism with female rodents being much less sensitive to doxorubicin than male rodents [15-17]. Similarly, female mice were protected against iron overload-induced cardiomyopathy [18]. On the other hand, both male and female rats developed cardiac hypertrophy at 4 and 16 weeks of chronic volume overload. Interestingly, the increase in cardiac muscle mass was greater in females than males at 16 weeks. At 4 weeks of chronic volume overload, however, a decrease in fractional shortening occurred in males only [19]. Pressure overload has been shown to increase left ventricular mass to the same extent in male and female rodents, but with a more marked decline in cardiac function in males [20, 21]. These studies clearly demonstrate that sex-related differences are model-specific.

Isoproterenol-induced cardiac dysfunction is an established model of excessive catecholamine-induced cardiovascular disease [22-24]. While low doses of isoproterenol (0.04
mg/kg/day for 6 months) cause cardiac hypertrophy and fibrosis without significant cardiac
dysfunction [10, 11], moderate doses (4 - 60 mg/kg/day) induce cardiac dysfunction and heart
failure [22, 25-27] and high doses (150 – 300 mg/kg/day) induce a model of myocardial infarction
[26, 28]. In the current work, we determined key sex-related differences in the acute response to
isoproterenol injection as well as the response to chronic administration of isoproterenol (10
mg/kg/day) for 2 weeks to C57Bl/6 mice. After acute administration of isoproterenol, we found out
that there was a similar increase in cardiac function parameters such as ejection fraction and
fractional shortening as well as a similar increase in heart rates in both male and female mice. In
agreement with these findings, isoproterenol induced similar acute hemodynamic changes in
male and female CD-1 mice [13]. Isolated adult rat hearts showed similar chronotropic and
inotropic responses to isoproterenol [29]. Male sex was associated with blunted β-adrenergic
receptor responsiveness to isoproterenol injection in human volunteers [30]. Contrariwise,
cardiomyocytes isolated from male rats had an augmented beta-adrenergic response to
isoproterenol [31]. These discrepancies may have arisen due to differences between the in vivo
and in vitro models employed in these studies.

We have also determined the response to chronic isoproterenol administration in male
and female mice. Our data demonstrate that chronic isoproterenol administration caused a similar
extent of cardiac dysfunction and cardiac hypertrophy in both male and female mice. Continuous
isoproterenol administration by mini-osmotic pumps (30 mg/kg/day) to C57Bl/6J mice for one
week caused cardiac hypertrophy in both male and female mice; however, females developed
significantly less hypertrophy than males [32]. Importantly, this regimen increased fractional
shortening in males, but not in female mice [32]. Chronic administration of low isoproterenol doses
(0.04 mg/kg/day for 6 months) from 9 to 15 months of age induced cardiac hypertrophy and
dilation in male Spontaneously hypertensive rats (SHRs), but not in females [11]. At the molecular
levels, we showed that chronic isoproterenol administration induced the gene expression of the natriuretic peptides, ANP and BNP, to a similar extent in hearts of male and female mice.

In addition to cardiac dysfunction and hypertrophy, male and female C57Bl/6 mice developed a similar degree of myocardial fibrosis in response to chronic isoproterenol administration. There are discrepant reports about the sex-dependent effect of chronic isoproterenol administration on cardiac fibrosis. On one hand, female CD-1 mice showed higher fibrosis than males after chronic isoproterenol administration 7.5 mg/kg/day for 3 weeks [13]. On the other hand, chronic isoproterenol administration 0.04 mg/kg/day for 6 months increased interstitial collagen in male SHRs, but not in females [11]. This discrepancy suggests that sex-related differences in the response to isoproterenol may be dose-dependent, with higher isoproterenol doses causing more severe damage that is not sexually dimorphic. It may also be attributed to strain difference, since male SHRs have a higher extent of baseline collagen content and cardiac hypertrophy than females [33]. In agreement with the similar effect on myocardial fibrosis, we also demonstrated that isoproterenol administration induced the gene expression of several fibrotic markers in hearts of male and female mice to a similar degree. We have also shown that MAC-2 positive cells were equally elevated in the hearts of male and female mice. MAC-2 expression has been shown to be highly associated with myocardial fibrosis [34, 35], although its causative role in inducing myocardial fibrosis is still controversial [36].

In order to identify the potential role of male sex hormones, we determined the response to chronic isoproterenol administration in castrated male mice compared to sham-operated animals. Intriguingly, there was no significant difference in the isoproterenol-induced cardiac dysfunction between castrated and sham-operated mice. In agreement with our results, castration had no effect on LV dilation produced by chronic isoproterenol administration 0.015 mg/kg/day for 6 months in Sprague Dawley rats [37]. In contrast, castration prevented cardiac hypertrophy, LV dilation, and increased interstitial collagen produced by chronic isoproterenol administration.
0.04 mg/kg/day for 6 months male SHRs [10]. These effects may be attributed to the protective effect of castration on the underlying cardiovascular pathology in male SHR, as previously reported [38], rather than the response to isoproterenol.

In order to identify the role of female sex hormones, we studied the effects of isoproterenol administration in ovariectomized female mice compared to sham-operated controls. Similar to castration in male mice, ovariectomy had no significant effect on isoproterenol-induced cardiac dysfunction. Similar to our findings, ovariectomy did not change the response to chronic isoproterenol administration in female SHRs [10]. Contrariwise, ovariectomized rats developed more extensive cardiac remodeling than intact females in response to chronic volume overload [39]. Estrogen exerted concentration-dependent pro- and anti-hypertrophic response in cultured adult cardiomyocytes isolated from male and female rats [40]. Low estrogen concentrations 1 pM had a pro-hypertrophic effect, whereas high concentration 1 nM prevented phenylephrine-induced hypertrophy [40]. Estrogen has also been shown to exert a model-dependent effect. Estrogen prevented cardiac hypertrophy and dysfunction caused by pressure overload, but not by myocardial infarction [41]. Although the results of these gonadectomy experiments corroborated our previous findings in intact animals, the small sample size and the lack of saline-treated control mice are limitations to the current work. Therefore, future studies are planned to specifically determine the effects of gonadectomy on isoproterenol-induced cardiac dysfunction and remodeling and to identify the molecular determinants of these effects.

**Conclusion**

The current study demonstrates lack of significant sex-related differences in cardiac hypertrophy, dysfunction, and fibrosis in response to moderate-dose isoproterenol (10 mg/kg/day for 14 days) in C57Bl/6 mice. Our findings also demonstrate that gonadectomy of male and female mice did not have a significant impact on isoproterenol-induced cardiac dysfunction. This study
suggests that female sex may not be sufficient to protect the heart against a severe pathologic stimulus, which may explain why women are susceptible to Takotsubu cardiomyopathy [3]. It also signifies the notion that sexual dimorphism in cardiovascular diseases is highly model-dependent.
Declarations

Ethics approval and consent to participate: All experimental procedures involving animals have been approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Minnesota.

Consent for publication: Not applicable.

Availability of data and material: The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests: The authors declare that they have no competing interests.

Funding: Research reported in this publication was supported by the National Institutes of Health’s National Center for Advancing Translational Sciences, grant UL1TR002494. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health’s National Center for Advancing Translational Sciences.

Authors’ contributions: MG conducted experiments and contributed to writing the manuscript, IA and CL conducted experiments, DS assessed the histopathology sections, BZ participated in research design, analyzed the data, and contributed to writing the manuscript. All authors read and approved the final manuscript.

Acknowledgements: Experiments using the NanoDrop 8000, ABI 7900 HT, and Agilent 2100 Bioanalyzer were done with staff support at the University of Minnesota Genomics Center. Experiments using the Vevo 2100 echocardiography system were done with staff support at the University of Minnesota Imaging Center. Processing of heart tissues for histopathological analysis
was performed with staff support at the Comparative Pathology Shared Resource, University of Minnesota Masonic Cancer Center.
1. Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abersa SF, Abyu G, et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1-25. doi: 10.1016/j.jacc.2017.04.052. PubMed PMID: 28527533; PubMed Central PMCID: PMCPMC5491406.

2. Fazal L, Azibani F, Vodовар N, Cohen Solal A, Delcayre C, Samuel JL. Effects of biological sex on the pathophysiology of the heart. Br J Pharmacol. 2014;171(3):555-66. doi: 10.1111/bph.12279. PubMed PMID: 23763376; PubMed Central PMCID: PMCPMC3969072.

3. Lyon AR, Bossone E, Schneider B, Sechtem U, Citro R, Underwood SR, et al. Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2016;18(1):8-27. doi: 10.1002/ejhf.424. PubMed PMID: 26548803.

4. Park JJ, Park SJ, Choi DJ. Microvascular angina: angina that predominantly affects women. Korean J Intern Med. 2015;30(2):140-7. doi: 10.3904/kjim.2015.30.2.140. PubMed PMID: 25750553; PubMed Central PMCID: PMCPMC4351318.

5. Taylor AL. Heart failure in women. Curr Heart Fail Rep. 2015;12(2):187-95. doi: 10.1007/s11897-015-0252-x. PubMed PMID: 25633565.

6. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progesterin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280(7):605-13. doi: 10.1001/jama.280.7.605. PubMed PMID: 9718051.

7. Bell JR, Mellor KM, Wollermann AC, Ip WT, Reichelt ME, Meachem SJ, et al. Aromatase deficiency confers paradoxical postischemic cardioprotection. Endocrinology. 2011;152(12):4937-47. doi: 10.1210/en.2011-1212. PubMed PMID: 22028441.

8. Kang NN, Fu L, Xu J, Han Y, Cao JX, Sun JF, et al. Testosterone improves cardiac function and alters angiotensin II receptors in isoproterenol-induced heart failure. Arch Cardiovasc Dis. 2012;105(2):68-76. doi: 10.1016/j.acvd.2011.12.002. PubMed PMID: 22424324.

9. Wang Y, Hu Y, Zeng Z, Li Y, Su H, Li Y, et al. Influence of androgen on myocardial apoptosis and expression of myocardial IR and IRS1 in chronic heart failure rat models. Mol Med Rep. 2018;17(1):1057-64. doi: 10.3892/mmr.2017.8018. PubMed PMID: 29115626.

10. Magubane M, Michel FS, Erlwanger KH, Norton GR, Woodiwiss AJ. Prevention of beta-adrenergic-induced Adverse Cardiac Remodeling by Gonadectomy in Male but Not Female Spontaneously Hypertensive Rats. J Cardiovasc Pharmacol. 2017;70(3):202-9. doi: 10.1097/FJC.0000000000000506. PubMed PMID: 28590262.

11. Michel FS, Magubane M, Mokotedi L, Norton GR, Woodiwiss AJ. Sex-Specific Effects of Adrenergic-Induced Left Ventricular Remodeling in Spontaneously Hypertensive Rats. J Card Fail. 2017;23(2):161-8. doi: 10.1016/j.cardfail.2016.09.017. PubMed PMID: 27663100.

12. Maass AH, Ikeda K, Oberdorf-Maass S, Maier SK, Leinwand LA. Hypertrophy, fibrosis, and sudden cardiac death in response to pathological stimuli in mice with mutations in cardiac troponin T. Circulation. 2004;110(15):2102-9. doi: 10.1161/01.CIR.0000144460.84795.E3. PubMed PMID: 15466629.

13. Horii Y, Uechi M, Ebisawa T, Yamano S, Yoshioka K, Mutoh K. The influence of gender on cardiac fibrosis induced by sympathetic stimulation. Chin J Physiol. 2008;51(3):146-51. PubMed PMID: 18935909.

14. Ishikawa K, Chemaly ER, Tilemann L, Fish K, Ladage D, Aguero J, et al. Assessing left ventricular systolic dysfunction after myocardial infarction: are ejection fraction and dP/dt(max) complementary or
15. Grant MK, Seelig DM, Sharkey LC, Zordoky BN. Sex-dependent alteration of cardiac cytochrome P450 gene expression by doxorubicin in C57Bl/6 mice. Biol Sex Differ. 2017;8:1. doi: 10.1186/s13293-016-0124-4. PubMed PMID: 28078076.

16. Zordoky BN, Radin MJ, Heller L, Tobias A, Matise I, Apple FS, et al. The interplay between genetic background and sexual dimorphism of doxorubicin-induced cardiotoxicity. Cardiooncology. 2016;2. doi: 10.1186/s40959-016-0013-3. PubMed PMID: 28758028; PubMed Central PMCID: PMCPMC5533296.

17. Moulin M, Piquereau J, Mateo P, Fortin D, Rucker-Martin C, Gressette M, et al. Sexual dimorphism of doxorubicin-mediated cardiotoxicity: potential role of energy metabolism remodeling. Circ Heart Fail. 2015;8(1):98-108. doi: 10.1161/CIRCHEARTFAILURE.114.001180. PubMed PMID: 25420486.

18. Das SK, Patel VB, Basu R, Wang W, DesAulniers J, Kassiri Z, et al. Females Are Protected From Iron-Overload Cardiomyopathy Independent of Iron Metabolism: Key Role of Oxidative Stress. J Am Heart Assoc. 2017;6(1). doi: 10.1161/JAHA.116.003456. PubMed PMID: 28115312; PubMed Central PMCID: PMCPMC5523622.

19. Dent MR, Tappia PS, Dhalla NS. Gender differences in cardiac dysfunction and remodeling due to volume overload. J Card Fail. 2010;16(5):439-49. doi: 10.1016/j.cardfail.2009.12.017. PubMed PMID: 20447581.

20. Weinberg EO, Thienelt CD, Katz SE, Bartunek J, Tajima M, Rohrbach S, et al. Gender differences in molecular remodeling in pressure overload hypertrophy. J Am Coll Cardiol. 1999;34(1):264-73. PubMed PMID: 10400020.

21. Loyer X, Gomez AM, Milliez P, Fernandez-Velasco M, Vangheluwe P, Vinet L, et al. Cardiomyocyte overexpression of neuronal nitric oxide synthase delays transition toward heart failure in response to pressure overload by preserving calcium cycling. Circulation. 2008;117(25):3187-98. doi: 10.1161/CIRCULATIONAHA.107.741702. PubMed PMID: 18541744.

22. Oudit GY, Crackower MA, Eriksson U, Sarao R, Kozieradzki I, Sasaki T, et al. Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure. Circulation. 2003;108(17):2147-52. doi: 10.1161/01.CIR.0000091403.62293.2B. PubMed PMID: 12963636.

23. Faulx MD, Ernsberger P, Vatner D, Hoffman RD, Lewis W, Strachan R, et al. Strain-dependent beta-adrenergic receptor function influences myocardial responses to isoproterenol stimulation in mice. Am J Physiol Heart Circ Physiol. 2005;289(1):H30-6. doi: 10.1152/ajpheart.00636.2004. PubMed PMID: 15749746.

24. Chen SW, Tung YC, Jung SM, Chu Y, Lin PJ, Kao WW, et al. Lumican-null mice are susceptible to aging and isoproterenol-induced myocardial fibrosis. Biochem Biophys Res Commun. 2017;482(4):1304-11. doi: 10.1016/j.bbrc.2016.12.033. PubMed PMID: 27939890.

25. He R, Ding C, Yin P, He L, Xu Q, Wu Z, et al. MiR-1a-3p mitigates isoproterenol-induced heart failure by enhancing the expression of mitochondrial ND1 and COX1. Exp Cell Res. 2019;378(1):87-97. doi: 10.1016/j.yexcr.2019.03.012. PubMed PMID: 30853447.

26. Park SW, Persaud SD, Ogokeh S, Meyers TA, Townsend D, Wei LN. CRABP1 protects the heart from isoproterenol-induced acute and chronic remodeling. J Endocrinol. 2018;236(3):151-65. doi: 10.1530/JEO-17-0613. PubMed PMID: 29371236; PubMed Central PMCID: PMCPMC5815894.

27. Nakata TM, Suzuki K, Uemura A, Shimada K, Tanaka R. Contrasting Effects of Inhibition of Phosphodiesterase 3 and 5 on Cardiac Function and Interstitial Fibrosis in Rats With Isoproterenol-Induced Cardiac Dysfunction. J Cardiovasc Pharmacol. 2019;73(3):195-205. doi: 10.1097/FJC.0000000000000652. PubMed PMID: 30839513.
28. Caillard A, Sadoune M, Cescau A, Meddour M, Gandon M, Polidano E, et al. QSOX1, a novel actor of cardiac protection upon acute stress in mice. J Mol Cell Cardiol. 2018;119:75-86. doi: 10.1016/j.yjmcc.2018.04.014. PubMed PMID: 29723491.

29. Elmes MJ, Haase A, Gardner DS, Langley-Evans SC. Sex differences in sensitivity to beta-adrenergic agonist isoproterenol in the isolated adult rat heart following prenatal protein restriction. Br J Nutr. 2009;101(5):725-34. doi: 10.1017/S0007114508025075. PubMed PMID: 18590591.

30. Sherwood A, Hill LK, Blumenthal JA, Johnson KS, Hinderliter AL. Race and sex differences in cardiovascular alpha-adrenergic and beta-adrenergic receptor responsiveness in men and women with high blood pressure. J Hypertens. 2017;35(5):975-81. doi: 10.1097/HJH.0000000000001266. PubMed PMID: 28306633; PubMed Central PMCID: PMCPMC5785915.

31. Vizgirda VM, Wahler GM, Sondgeroth KL, Ziolo MT, Schwertz DW. Mechanisms of sex differences in rat cardiac myocyte response to beta-adrenergic stimulation. Am J Physiol Heart Circ Physiol. 2002;282(1):H256-63. doi: 10.1152/ajpheart.2002.282.1.H256. PubMed PMID: 11748070.

32. Haines CD, Harvey PA, Leinwand LA. Estrogens mediate cardiac hypertrophy in a stimulus-dependent manner. Endocrinology. 2012;153(9):4480-90. doi: 10.1210/en.2012-1353. PubMed PMID: 22759381; PubMed Central PMCID: PMCPMC3423609.

33. Al-Gburi S, Deussen AJ, Galli R, Muders MH, Zatschler B, Neisser A, et al. Sex-specific differences in age-dependent progression of aortic dysfunction and related cardiac remodeling in spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol. 2017;312(5):R835-R49. doi: 10.1152/ajpregu.00231.2016. PubMed PMID: 28274938.

34. Vergaro G, Prud'homme M, Fazal L, Passino C, Emdin M, et al. Inhibition of Galectin-3 Pathway Prevents Isoproterenol-Induced Left Ventricular Dysfunction and Fibrosis in Mice. Hypertension. 2016;67(3):606-12. doi: 10.1161/HYPERTENSIONAHA.115.06161. PubMed PMID: 26781273.

35. Yu L, Ruifrok WP, Meissner M, van Goor H, Sanjabi B, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail. 2013;6(1):107-17. doi: 10.1161/CIRCHEARTFAILURE.112.971168. PubMed PMID: 23230309.

36. Frunza O, Russo I, Saxena A, Shinde AV, Humere C, Hanif W, et al. Myocardial Galectin-3 Expression Is Associated with Remodeling of the Pressure-Overloaded Heart and May Delay the Hypertrophic Response without Affecting Survival, Dysfunction, and Cardiac Fibrosis. Am J Pathol. 2016;186(5):1114-27. doi: 10.1016/j.ajpath.2015.12.017. PubMed PMID: 26948424; PubMed Central PMCID: PMCPMC4861760.

37. Hodson B, Woodiwiss AJ, Norton GR, Michel FS. Impact of castration on changes in left ventricular diastolic pressure-volume relations induced by chronic adrenergic stimulation in rats. J Cardiovasc Pharmacol. 2014;63(6):562-6. doi: 10.1097/FJC.0000000000000081. PubMed PMID: 24477046.

38. Dalpiaz PL, Lamas AZ, Caliman IF, Ribeiro RF, Jr., Abreu GR, Moyses MR, et al. Sex Hormones Promote Opposite Effects on ACE and ACE2 Activity, Hypertrophy and Cardiac Contractility in Spontaneously Hypertensive Rats. PLoS One. 2015;10(5):e0127515. doi: 10.1371/journal.pone.0127515. PubMed PMID: 26010093; PubMed Central PMCID: PMCPMC4444272.

39. Brower GL, Gardner JD, Janicki JS. Gender mediated cardiac protection from adverse ventricular remodeling is abolished by ovariectomy. Mol Cell Biochem. 2003;251(1-2):89-95. PubMed PMID: 14575309.

40. Kilic A, Javadov S, Karmazyn M. Estrogen exerts concentration-dependent pro-and anti-hypertrophic effects on adult cultured ventricular myocytes. Role of NHE-1 in estrogen-induced hypertrophy. J Mol Cell Cardiol. 2009;46(3):360-9. doi: 10.1016/j.yjmcc.2008.11.018. PubMed PMID: 19111554.
Patten RD, Pourati I, Aronovitz MJ, Alsheikh-Ali A, Eder S, Force T, et al. Beta-estradiol differentially affects left ventricular and cardiomyocyte hypertrophy following myocardial infarction and pressure overload. J Card Fail. 2008;14(3):245-53. doi: 10.1016/j.cardfail.2007.10.024. PubMed PMID: 18381189; PubMed Central PMCID: PMCPMC4181711.
FIGURE LEGENDS

Figure 1. Acute administration of isoproterenol causes a similar cardiac response in male and female mice. Cardiac function in adult male (n=6) and female (n=6) C57Bl/6 mice was assessed by trans-thoracic echocardiography just prior to and immediately following a single subcutaneous injection of 10 mg/kg isoproterenol (ISO). (A) Representative images from parasternal short axis view of the heart acquired in M-Mode. Effects of ISO on (B) ejection fraction, (C) fractional shortening, (D) LV volume in end-systole, (E) LV volume in end-diastole, (F) cardiac output, and (G) heart rate. Values are shown as means ± SEM. *p<0.05, compared to before treatment of the same sex by matched two-way ANOVA with Sidak’s post-hoc analysis.

Figure 2. Chronic administration of isoproterenol causes similar cardiac dysfunction in male and female mice. Male and female C57Bl/6 mice were subcutaneously injected with 10 mg/kg isoproterenol (ISO) (male, female n=12) or saline (male, female n=7) daily for 14 days. (A-F) Cardiac function was assessed by trans-thoracic echocardiography. (A) Representative images from parasternal short axis view of the heart acquired in M-Mode. Effects of ISO on (B) ejection fraction, (C) fractional shortening, (D) LV volume in end-systole, (E) LV volume in end-diastole, (F) cardiac output, and (G) LV mass. (H) Heart weight to tibial length ratio. Values are shown as means ± SEM. *p<0.05, compared to control treatment of the same sex; # p<0.05, compared to male of same treatment by two-way ANOVA with Tukey’s post-hoc analysis.

Figure 3. Chronic administration of isoproterenol causes similar histopathologic changes in hearts of male and female mice. Male and female C57Bl/6 mice were subcutaneously injected with 10 mg/kg isoproterenol (ISO) (male, female n=6, 5, respectively) or saline (male, female n=5) daily for 14 days. Figure 3 shows representative images from hematoxylin and eosin (HE), Masson’s trichrome, and MAC-2 stained sections.
Figure 4. Chronic administration of isoproterenol causes similar levels of fibrosis and MAC-2 accumulation in hearts of male and female mice. Male and female C57Bl/6 mice were subcutaneously injected with 10 mg/kg isoproterenol (ISO) (male, female n=6, 5, respectively) or saline (male, female n=5) daily for 14 days. (A) Isoproterenol treated male and female C57Bl/6 mice demonstrate increased collagen (light blue, Masson’s trichrome) deposition and (B) increased numbers of MAC-2 positive cells compared to control mice. *p<0.05, compared to control treatment of the same sex, by non-parametric Kruskal-Wallis test.

Figure 5. Chronic administration of isoproterenol causes similar changes in gene expression of the natriuretic peptides and fibrotic markers in hearts of male and female mice. Male and female C57Bl/6 mice were given subcutaneous injections of 10 mg/kg isoproterenol (ISO) or saline (control) daily for 14 days (n=5-6 per group). mRNA expression of (A) ANP, (B) BNP, (C) TGF-beta1 mouse hearts. Results are normalized to beta-actin and expressed relative to male control. Values are shown as means ± SEM. *p<0.05, compared to control treatment of the same sex.

Figure 6. Chronic administration of isoproterenol causes similar cardiac dysfunction in castrated or sham-operated male mice. (A-F) Cardiac function in adult male castrated (CAST) (n=4) and sham-operated (n=4) C57Bl/6 mice was assessed by trans-thoracic echocardiography one week prior to treatment (Pre-ISO), and again after 2 weeks of daily subcutaneous injections of 10 mg/kg isoproterenol (Post-ISO). (A) Representative images from parasternal short axis view of the heart acquired in M-Mode. Effects of ISO on (B) ejection fraction, (C) fractional shortening, (D) LV volume in end-systole, (E) LV volume in end-diastole, (F) cardiac output, and (G) LV mass. *p<0.05, compared to before treatment of the same surgical status by matched two-way ANOVA with Sidak’s post-hoc analysis.

Figure 7. Chronic administration of isoproterenol causes similar cardiac dysfunction in ovariectomized or sham-operated female mice. (A-F) Cardiac function in adult female
ovariectomized (OVX) (n=3) and sham-operated (n=4) C57Bl/6 mice was assessed by transthoracic echocardiography one week prior to treatment (Pre-ISO), and again after 2 weeks of daily subcutaneous injections of 10 mg/kg isoproterenol (Post-ISO). (A) Representative images from parasternal short axis view of the heart acquired in M-Mode. Effects of ISO on (B) ejection fraction, (C) fractional shortening, (D) LV volume in end-systole, (E) LV volume in end-diastole, (F) cardiac output, and (G) LV mass. *p<0.05, compared to before treatment of the same surgical status by matched two-way ANOVA with Sidak’s post-hoc analysis.
Supplemental Digital Content:

Supplementary Tables
Figure 1

(A) Pre-ISO vs. Post-ISO images for male and female groups.

(B) Ejection Fraction (%)

(C) Fractional Shortening (%)

(D) LV volume: end-systole (ul)

(E) LV volume: end-diastole (ul)

(F) Cardiac Output (ml/min)

(G) Heart Rate (bpm)
Figure 2

(A) Control vs. ISO for different genders (MALE and FEMALE).

(B) Ejection Fraction (%)
- Male: Control, ISO
- Female: Control, ISO

(C) Fractional Shortening (%)
- Male: Control, ISO
- Female: Control, ISO

(D) LV Volume: end-systole (ul)
- Male: Control, ISO
- Female: Control, ISO

(E) LV Volume: end-diastole (ul)
- Male: Control, ISO
- Female: Control, ISO

(F) Cardiac Output (ml/min)
- Male: Control, ISO
- Female: Control, ISO

(G) LV Mass (mg)
- Male: Control, ISO
- Female: Control, ISO

(H) Heart Weight / Tibia Length (mg/mm)
- Male: Control, ISO
- Female: Control, ISO

* indicates a significant difference between Control and ISO groups.
Figure 3

|       | Male               | Female              |
|-------|--------------------|---------------------|
| Control | ![Image](image1)  | ![Image](image2)  |
| Isoproterenol | ![Image](image3)  | ![Image](image4)  |
|       | ![Image](image5)  | ![Image](image6)  |
| Trichrome | ![Image](image7)  | ![Image](image8)  |
|       | ![Image](image9)  | ![Image](image10) |
| MAC-2  | ![Image](image11) | ![Image](image12) |

Figure 3
Figure 6

(A) Pre-ISO

SHAM

CASTRATED

Pre-ISO

Post-ISO

(B) Ejection Fraction (%)

SHAM

Castrated

Pre-Chronic ISO

Post-Chronic ISO

(C) Fractional Shortening (%)

SHAM

Castrated

Pre-Chronic ISO

Post-Chronic ISO

(D) LV Volume (ml)

SHAM

Castrated

Pre-Chronic ISO

Post-Chronic ISO

(E) LV Volume (ml)

SHAM

Castrated

Pre-Chronic ISO

Post-Chronic ISO

(F) Cardiac Output (mL/min)

SHAM

Castrated

Pre-Chronic ISO

Post-Chronic ISO

(G) LV Mass (g)

SHAM

Castrated

Pre-Chronic ISO

Post-Chronic ISO
